Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: EloraTZP · Obesity or Overweight and Type 2 Diabetes Trial sites expanded: 75 → 96 locations Eli Lilly and CompanyPhase 3 NCT07881458
  2. Minor: QTX-2101 · Acute Promyelocytic Leukemia Trial sites expanded: 36 → 39 locations Quetzal TherapeuticsPhase 3 NCT07504458
  3. Minor: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Trial sites expanded: 314 → 317 locations Merck Sharp & Dohme LLCPhase 3 NCT06393374
  4. Minor: Ivonescimab for First-line Treatment of Metastatic NSCLC · High PD-L1 Trial sites expanded: 285 → 292 locations Summit TherapeuticsPhase 3 NCT06767514
  5. Minor: Stroke and Systemic Embolism Prevention · Atrial Fibrillation Trial sites expanded: 66 → 84 locations Regeneron PharmaceuticalsPhase 3 NCT07626411
  6. Minor: How a New Pneumococcal Vaccine Works in Infants Trial sites expanded: 130 → 134 locations PfizerPhase 3 NCT07629440
  7. Minor: Ravulizumab · Primary IgAN Trial sites expanded: 15 → 19 locations Alexion Pharmaceuticals, Inc.Phase 3 NCT07024563
  8. Minor: ELEVATE-LIVER · Survodutide Helps Improve Heart Structure and Function · Overweight or Obesity and Fatty Liver Disease Trial sites expanded: 45 → 55 locations Boehringer IngelheimPhase 3 NCT07850063
  9. Minor: Pegozafermin · Compensated Cirrhosis Due to MASH Trial sites expanded: 330 → 335 locations Hoffmann-La RochePhase 3 NCT06419374
  10. Minor: Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens · Relapsed/Refractory Multiple Myeloma (RRMM) Trial sites expanded: 53 → 60 locations Regeneron PharmaceuticalsPhase 3 NCT07222761
  11. Minor: Intravitreal Injection of 4D-150 · Diabetic Macular Edema (DME) Trial sites expanded: 92 → 95 locations 4D Molecular TherapeuticsPhase 3 NCT07867080
  12. Minor: KarXT · Manic Episodes in Bipolar-I Disorder (BALSAM-3) Trial sites expanded: 182 → 191 locations Bristol-Myers SquibbPhase 3 NCT06929273
  13. Minor: Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone · Newly Diagnosed Previously Untreated Primary Immune Thrombocytopenia (ITP) Trial sites expanded: 3 → 21 locations AmgenPhase 3 NCT07700238
  14. Minor: CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis Trial sites expanded: 35 → 40 locations Medipost, Inc.Phase 3 NCT07339111
  15. Minor: Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy Trial sites expanded: 28 → 46 locations argenxPhase 2 NCT07287982
  16. Minor: Mivelsiran · Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) Trial sites expanded: 10 → 20 locations Alnylam PharmaceuticalsPhase 2 NCT07636811
  17. Minor: Linvoseltamab is Safe and Works · Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Trial sites expanded: 21 → 24 locations Regeneron PharmaceuticalsPhase 1/2 NCT06292780
  18. Minor: IMG-007 · Moderate-to-Severe Atopic Dermatitis Trial sites expanded: 30 → 33 locations Inmagene LLCPhase 2 NCT07037901
  19. Minor: Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) Trial sites expanded: 20 → 26 locations Alpha Cognition, IncPhase 4 NCT07633470
  20. Minor: If an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, · Advanced Malignant Tumors Trial sites expanded: 76 → 79 locations BioNTech SEPhase 1/2 NCT07070232
  21. Minor: NBI-1065890 Versus Placebo · Tardive Dyskinesia Trial sites expanded: 35 → 48 locations Neurocrine BiosciencesPhase 2 NCT07365462
  22. Minor: Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Trial sites expanded: 276 → 279 locations Spyre Therapeutics, Inc.Phase 2 NCT07012395
  23. Minor: GTX-B001 in Healthy Subjects and · Chronic Inducible Urticaria Trial sites expanded: 3 → 6 locations Granular Therapeutics LimitedPhase 1 NCT07181369
  24. Minor: 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors Trial sites expanded: 8 → 12 locations Zai Lab (Shanghai) Co., Ltd.Phase 1 NCT07374848
  25. Minor: PF-08165784 · PIK3CA-Mutated Advanced or Metastatic Solid Tumors Trial sites expanded: 0 → 5 locations PfizerPhase 1 NCT07897721